Ribon Therapeutics Secures $65 Million Financing

– Proceeds Support Advancement of Lead Product Candidates RBN-2397 and RBN-3143 Through Key Clinical Milestones

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, announced the closing of a $65 million financing. The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation – JJDC, Inc., Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group. Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.

“We are excited to have this terrific group of new investors join our strong group of existing investors to enable Ribon to develop novel precision drugs targeting stress support pathways,” said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “The additional capital will enable the advancement of our lead programs, RBN-2397 in cancer and RBN-3143 in inflammation, through key clinical milestones as well as support additional drug discovery and validation from our proprietary BEACON⁺ platform. We look forward to realizing our mission to bring novel small molecule therapeutics to patients and families in need.”

“Ribon is pioneering the development of first-in-class precision development candidates targeting stress support pathways in cancer and inflammation and has made notable progress advancing its lead candidates,” said Cameron Wheeler, Ph.D., Partner, Deerfield Management and Board Director for Ribon Therapeutics. “This funding represents a commitment to the compelling science that marks the foundation of Ribon and we look forward to working with management on continued clinical, preclinical and platform discovery execution.”

About Ribon Therapeutics

Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging our proprietary BEACON⁺ (Blocking the Enzyme Activity Component of NAD⁺) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD⁺-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts. For more information visit www.RibonTx.com.

Contacts

Brendan Burns

Argot Partners

212.600.1902

[email protected]